ES2253443T3 - Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. - Google Patents
Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.Info
- Publication number
- ES2253443T3 ES2253443T3 ES01987668T ES01987668T ES2253443T3 ES 2253443 T3 ES2253443 T3 ES 2253443T3 ES 01987668 T ES01987668 T ES 01987668T ES 01987668 T ES01987668 T ES 01987668T ES 2253443 T3 ES2253443 T3 ES 2253443T3
- Authority
- ES
- Spain
- Prior art keywords
- antiprogestin
- treatment
- breast cancer
- tumor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 48
- 229940088597 hormone Drugs 0.000 title description 26
- 239000005556 hormone Substances 0.000 title description 26
- 230000001419 dependent effect Effects 0.000 title description 23
- 201000010099 disease Diseases 0.000 title description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 23
- 239000003418 antiprogestin Substances 0.000 claims abstract description 105
- 230000000708 anti-progestin effect Effects 0.000 claims abstract description 104
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- 238000011321 prophylaxis Methods 0.000 claims abstract description 20
- -1 11- (4-acetylphenyl) -17-hydroxy-17- (1, 1, 2, 2, 2-pentafluoroethyl) -estra-4, 9-diene-3-one Chemical compound 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 3
- 230000036512 infertility Effects 0.000 claims abstract description 3
- 208000000509 infertility Diseases 0.000 claims abstract description 3
- 231100000535 infertility Toxicity 0.000 claims abstract description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 3
- 230000000624 ovulatory effect Effects 0.000 claims abstract description 3
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 19
- 239000000328 estrogen antagonist Substances 0.000 claims description 19
- 229940046836 anti-estrogen Drugs 0.000 claims description 18
- 210000000481 breast Anatomy 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 230000003637 steroidlike Effects 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 58
- 206010006187 Breast cancer Diseases 0.000 abstract description 51
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 238000009806 oophorectomy Methods 0.000 description 28
- 241000700159 Rattus Species 0.000 description 25
- 229960001603 tamoxifen Drugs 0.000 description 17
- 230000004614 tumor growth Effects 0.000 description 16
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 15
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 15
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 229950011093 onapristone Drugs 0.000 description 9
- 230000002265 prevention Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000009036 growth inhibition Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 5
- 238000009577 estrogen deprivation therapy Methods 0.000 description 5
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000005748 tumor development Effects 0.000 description 5
- 238000012313 Kruskal-Wallis test Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229960003881 letrozole Drugs 0.000 description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960003248 mifepristone Drugs 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
- 229960004622 raloxifene Drugs 0.000 description 4
- 238000013223 sprague-dawley female rat Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003886 aromatase inhibitor Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000009261 endocrine therapy Methods 0.000 description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- AYRABHFHMLXKBT-UHFFFAOYSA-N 2,6-Dimethyl-anthracen Natural products C1=C(C)C=CC2=CC3=CC(C)=CC=C3C=C21 AYRABHFHMLXKBT-UHFFFAOYSA-N 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 2
- 108010078554 Aromatase Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 238000011770 Fox Chase SCID mouse Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000011430 maximum method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SEMWODVUFFPLLJ-BYYHNAKLSA-N 2-[4-[(e)-1,2-diphenylbut-1-enyl]phenoxy]-n,n-diethylethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/CC)C1=CC=CC=C1 SEMWODVUFFPLLJ-BYYHNAKLSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002800 anti-glucocorticoid effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099800P | 2000-10-18 | 2000-10-18 | |
| EP00250341 | 2000-10-18 | ||
| US240998P | 2000-10-18 | ||
| EP00250341 | 2000-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2253443T3 true ES2253443T3 (es) | 2006-06-01 |
Family
ID=26072951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01987668T Expired - Lifetime ES2253443T3 (es) | 2000-10-18 | 2001-10-17 | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7378406B2 (enExample) |
| EP (1) | EP1328276B1 (enExample) |
| JP (2) | JP2004511522A (enExample) |
| KR (1) | KR100632908B1 (enExample) |
| CN (1) | CN1512886A (enExample) |
| AT (1) | ATE310522T1 (enExample) |
| AU (2) | AU1824302A (enExample) |
| BG (1) | BG107743A (enExample) |
| BR (1) | BR0114665A (enExample) |
| CA (1) | CA2423017C (enExample) |
| CY (1) | CY1104981T1 (enExample) |
| CZ (1) | CZ299942B6 (enExample) |
| DE (1) | DE60115274T2 (enExample) |
| DK (1) | DK1328276T3 (enExample) |
| EE (1) | EE05259B1 (enExample) |
| ES (1) | ES2253443T3 (enExample) |
| HR (1) | HRP20030387A2 (enExample) |
| HU (1) | HUP0301460A3 (enExample) |
| IL (2) | IL154975A0 (enExample) |
| MX (1) | MXPA03002954A (enExample) |
| NO (1) | NO20031740L (enExample) |
| NZ (1) | NZ538346A (enExample) |
| PL (1) | PL360151A1 (enExample) |
| SI (1) | SI1328276T1 (enExample) |
| SK (1) | SK287124B6 (enExample) |
| WO (1) | WO2002032430A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| US9517240B2 (en) * | 2006-09-26 | 2016-12-13 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
| US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| JP2010524997A (ja) * | 2007-04-23 | 2010-07-22 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Ｂｒｃａ単独での、又は抗エストロゲン薬を伴った組み合わせ物としての使用のためのプロゲステロン受容体拮抗薬 |
| US20080261929A1 (en) * | 2007-04-23 | 2008-10-23 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| CN107260745A (zh) * | 2010-03-22 | 2017-10-20 | 利普生物药剂公司 | 用于抗孕酮的非毒性递送的组合物和方法 |
| US10328022B2 (en) | 2012-05-31 | 2019-06-25 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
| HK1211852A1 (en) | 2012-11-02 | 2016-06-03 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3733478A1 (de) * | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
-
2001
- 2001-10-17 ES ES01987668T patent/ES2253443T3/es not_active Expired - Lifetime
- 2001-10-17 DK DK01987668T patent/DK1328276T3/da active
- 2001-10-17 NZ NZ538346A patent/NZ538346A/en unknown
- 2001-10-17 JP JP2002535668A patent/JP2004511522A/ja not_active Ceased
- 2001-10-17 CA CA002423017A patent/CA2423017C/en not_active Expired - Fee Related
- 2001-10-17 IL IL15497501A patent/IL154975A0/xx active IP Right Grant
- 2001-10-17 MX MXPA03002954A patent/MXPA03002954A/es active IP Right Grant
- 2001-10-17 DE DE60115274T patent/DE60115274T2/de not_active Expired - Lifetime
- 2001-10-17 HR HR20030387A patent/HRP20030387A2/xx not_active Application Discontinuation
- 2001-10-17 SI SI200130486T patent/SI1328276T1/sl unknown
- 2001-10-17 KR KR1020037005359A patent/KR100632908B1/ko not_active Expired - Fee Related
- 2001-10-17 HU HU0301460A patent/HUP0301460A3/hu unknown
- 2001-10-17 CN CNA018175686A patent/CN1512886A/zh active Pending
- 2001-10-17 BR BR0114665-3A patent/BR0114665A/pt not_active Application Discontinuation
- 2001-10-17 US US10/399,320 patent/US7378406B2/en not_active Expired - Fee Related
- 2001-10-17 SK SK474-2003A patent/SK287124B6/sk not_active IP Right Cessation
- 2001-10-17 AT AT01987668T patent/ATE310522T1/de not_active IP Right Cessation
- 2001-10-17 CZ CZ20031072A patent/CZ299942B6/cs not_active IP Right Cessation
- 2001-10-17 EP EP01987668A patent/EP1328276B1/en not_active Expired - Lifetime
- 2001-10-17 PL PL36015101A patent/PL360151A1/xx not_active Application Discontinuation
- 2001-10-17 EE EEP200300155A patent/EE05259B1/xx not_active IP Right Cessation
- 2001-10-17 WO PCT/EP2001/012005 patent/WO2002032430A1/en not_active Ceased
- 2001-10-17 AU AU1824302A patent/AU1824302A/xx active Pending
- 2001-10-17 AU AU2002218243A patent/AU2002218243B2/en not_active Ceased
-
2003
- 2003-03-18 IL IL154975A patent/IL154975A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031740A patent/NO20031740L/no not_active Application Discontinuation
- 2003-04-18 BG BG107743A patent/BG107743A/bg unknown
-
2006
- 2006-02-22 CY CY20061100251T patent/CY1104981T1/el unknown
-
2009
- 2009-12-16 JP JP2009284779A patent/JP2010077158A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2253443T3 (es) | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. | |
| AU2002218243A1 (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
| US20070238714A1 (en) | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases | |
| ES2269492T3 (es) | Uso de 11beta-(4-acetilfenil)-17beta-hidroxi-17alfa-(1,1,2,2-pentafluoroetil)estra-4,9-dien-3-ona para la preparacion de un medicamento para el tratamiento del cancer de mama, cancer de ovario, cancer de endometrio, mieloma y meningioma. | |
| AU2002223619A1 (en) | Use of antiprogestins for the induction of apoptosis in a cell | |
| ZA200303793B (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases. | |
| US20080268041A1 (en) | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases | |
| HK1068098A (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
| TWI310685B (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
| JP2010524996A (ja) | Ｂｒｃａ媒介性疾患における使用のための、プロゲステロン受容体拮抗薬と、ルテインホルモン放出ホルモン作動薬および拮抗薬との組み合わせ |